These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 1534319

  • 1. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity.
    Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC.
    Int J Cancer; 1992 May 28; 51(3):433-8. PubMed ID: 1534319
    [Abstract] [Full Text] [Related]

  • 2. [SDZ PSC 833: a novel modulator of MDR].
    Covelli A.
    Tumori; 1997 May 28; 83(5 Suppl):S21-4. PubMed ID: 9446255
    [Abstract] [Full Text] [Related]

  • 3. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models.
    Watanabe T, Naito M, Oh-hara T, Itoh Y, Cohen D, Tsuruo T.
    Jpn J Cancer Res; 1996 Feb 28; 87(2):184-93. PubMed ID: 8609068
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
    Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM.
    J Clin Oncol; 1996 Feb 28; 14(2):610-8. PubMed ID: 8636778
    [Abstract] [Full Text] [Related]

  • 5. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
    Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F.
    Cancer Res; 1991 Aug 15; 51(16):4226-33. PubMed ID: 1678313
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
    Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M.
    J Clin Oncol; 1997 May 15; 15(5):1796-802. PubMed ID: 9164187
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
    Krishna R, Mayer LD.
    Cancer Res; 1997 Dec 01; 57(23):5246-53. PubMed ID: 9393743
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.
    Bauer KS, Karp JE, Garimella TS, Wu S, Tan M, Ross DD.
    Leuk Res; 2005 Mar 01; 29(3):263-71. PubMed ID: 15661261
    [Abstract] [Full Text] [Related]

  • 13. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats.
    Lemaire M, Bruelisauer A, Guntz P, Sato H.
    Cancer Chemother Pharmacol; 1996 Mar 01; 38(5):481-6. PubMed ID: 8765444
    [Abstract] [Full Text] [Related]

  • 14. Effect of SDZ PSC 833 ([3'-keto-Bmt1]-[Val2]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide in vitro.
    Watanabe T, Iwasaki M, Todaka T, Morikawa H, Ohtawa M.
    Anticancer Drugs; 1997 Apr 01; 8(4):400-4. PubMed ID: 9180396
    [Abstract] [Full Text] [Related]

  • 15. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia.
    Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P, Hiestand PC.
    Int J Cancer; 1992 Feb 20; 50(4):593-7. PubMed ID: 1347037
    [Abstract] [Full Text] [Related]

  • 16. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein.
    Archinal-Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itoh Y, Combates NJ, Bair KW, Cohen D.
    Oncol Res; 1995 Feb 20; 7(12):603-10. PubMed ID: 8704277
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
    Pein F, Pinkerton R, Berthaud P, Pritchard-Jones K, Dick G, Vassal G.
    Eur J Cancer; 2007 Sep 20; 43(14):2074-81. PubMed ID: 17716890
    [Abstract] [Full Text] [Related]

  • 19. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833.
    Gonzalez O, Colombo T, De Fusco M, Imperatori L, Zucchetti M, D'Incalci M.
    Cancer Chemother Pharmacol; 1995 Sep 20; 36(4):335-40. PubMed ID: 7628053
    [Abstract] [Full Text] [Related]

  • 20. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
    Colombo T, Gonzalez Paz O, D'Incalci M.
    Br J Cancer; 1996 Apr 20; 73(7):866-71. PubMed ID: 8611397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.